Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Fucosidosis Therapeutics Market Snapshot (2023 to 2033)

The global Fucosidosis Therapeutics Market is expected to garner a market value of US$ 10 Million in 2023 and is expected to accumulate a market value of US$ 17.91 Million by registering a CAGR of 6% in the forecast period 2023 to 2033. The market for Fucosidosis Therapeutics registered a CAGR of 4% in the historical period 2018 to 2022.

Studies state that Fucosidosis is a rare autosomal recessive lysosomal storage disorder characterized by a deficiency of alpha -L-fucosidase. Its estimated frequency is below 1 in 200,000 live births.

Report Attribute Details
Expected Market Value (2023) US$ 10 Million
Anticipated Forecast Value (2033) US$ 17.91 Million
Projected Growth Rate (2023 to 2033) 6% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Fucosidosis Therapeutics Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider Future Market Insights- the market for Fucosidosis Therapeutics reflected a value of 4% during the historical period, 2018 to 2022.

A series of international-level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Fucosidosis Therapeutics.

The market's growth is attributed to the factors such as expanding the area of advanced therapies along with gene delivery technologies and has developed progressive competition among key players focused on the commercialization of their therapies. The biotechnology companies are investing in acquisitions, mergers/collaborations, and expansions as key strategies to increase in-house expertise and strengthen product pipelines.

In its new study, ESOMAR-certified market research and consulting firm Future Market Insights (FMI) offers insights about key factors driving demand for Fucosidosis Therapeutics. In the years to come, increasing focus by government organizations and private agencies like WHO and pharmaceutical companies to create awareness of fucosidosis is fuelling the market growth. Thus, the market for Fucosidosis Therapeutics is expected to register a CAGR of 6% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of the Fucosidosis Therapeutics Market?

Increased Advancements in R&D technology to Push the Market Growth

Fucosidosis is caused by mutations in a gene known as FUCA1, which provides instructions for the production of an enzyme called alpha-L-fucosidase. Fucosidosis is one of nine identified glycoprotein storage diseases. The massive research and technology for glycoprotein analysis to unravel their structure and function is propelling immense growth. Also the advancing R&D technology and investments into Fucosidosis analysis for drugs therapies vaccines disease progression understanding the biology of glycoprotein and product launches.

Glycoprotein analysis has attracted huge Research and Development investments, subsidization, and reimbursements for glycoprotein-associated antibodies mutations and associated pathway targeting which altogether propels the market growth.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Faced by the Fucosidosis Therapeutics Market?

Expensive Cost of Treatment to restrict Market Growth

The expensive treatment of Fucosidosis Therapeutics, less awareness of Fucosidosis disease, and insubstantial treatment options are hampering the market growth. Furthermore, lack of health remuneration policies, rise in cost, and side effects associated with certain treatments is expected to hinder the market growth.

Region-Wise Insights

How is the Market for Fucosidosis Therapeutics Market Turning Out in the Asia Pacific Region?

Improvement in healthcare spending propelling the growth of Fucosidosis Therapeutics in Asia Pacific

The Asia Pacific is expected to exhibit a significant growth rate of all regions over the forecast period, with a CAGR of 5% during the forecast period. The growth is owed to increased awareness, significant increases in healthcare spending, and a rising frequency of the Fucosidosis Therapeutics Market in the region. Asia Pacific is an emerging market due to the increase in point care approach to health & care. An increasing number of hospitals in India and China makes a promising market for the market worldwide.

What are the Factors Boosting the Market for Fucosidosis Therapeutics in North America?

Technological Advancements Shaping Landscape for Fucosidosis Therapeutics in North America

North America is anticipated to acquire a market share of about 25% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region. In August 2022, GlycoNet, a pan-Canadian network of Centers of Excellence centered at UAlberta, received a USD 10.68 million investment from the Canadian Foundation for Innovation’s Major Science Initiative Fund to continue its mission of researching glycomics for the benefit of human health. Furthermore, due to the presence of leading technological advancements in the healthcare sector and healthcare facilities with the advancements in technology, efficient treatments are being introduced.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

By Therapy, Which Segment is Likely to Account for a Prominent Share?

Bone marrow transplantation is an effective therapy to drive the market

The bone marrow transplant procedure is prescribed for the treatment of advanced stages of leukemia, Fucosidosis, Hodgkin, and non-Hodgkin lymphomas, multiple myeloma, aplastic and sickle cell anemia, thalassemia, and other diseases. Increasing awareness, combined with an increase in initiatives run by healthcare practitioners, is majorly responsible for the global growth of the bone marrow transplant market. Therefore, it is anticipated that bone marrow transplant is likely to witness significant growth during the forecast period.

By End-user, Which Segment is Likely to Account for a Significant Share?

Hospitals to take the lead and drive market growth

According to the FMI analysis, Hospitals account for the largest market share. The requirement for several hospital stays and visits during the Fucosidosis Therapeutics facilitates the growth of this segment. Hospitals are also emphasizing the delivery of various comprehensive programs with personalized and professional support in the management of target diseases.

Market Competition

Key players in the Fucosidosis Therapeutics Market are Sigma-Aldrich. BD, Enzo Life Sciences, Creative Diagnostics, Thermo Fisher Scientific, Epitope Diagnostics Inc., R&D Systems, QED Bioscience Inc, and ACROBiosystems among other global players.

  • In April 2022, Bruker launched a novel MALDI HiPLEX-IHC tissue imaging solution for timsTOF flex using AmberGen’s HiPLEX-IHC peptide code antibody probes, combined with unbiased lipidomics, glycomics, and metabolomics tissue imaging.
  • In November 2019, Lonza Group Ltd. partnered with Cryoport, Inc. in the cell and gene therapy field and across Lonza's 'vein-to-vein' delivery network.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 10 Million
Market Value in 2033 US$ 17.91 Million
Growth Rate CAGR of 6% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in USD Million and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
  • Therapy
  • End-User
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa (MEA)
Key Countries Profiled
  • USA
  • Canada
  • Brazil
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • Nordics
  • BENELUX
  • Australia & New Zealand
  • China
  • India
  • Association of Southeast Asian Nations
  • Gulf Cooperation Council
  • South Africa
Key Companies Profiled
  • Sigma-Aldrich. BD
  • Enzo Life Sciences
  • Creative Diagnostics
  • Thermo Fisher Scientific
  • Epitope Diagnostics Inc.
  • Research and Development Systems
  • QED Bioscience Inc
  • ACROBiosystems.
Customization Available Upon Request

Key Segments Profiled in the Fucosidosis Therapeutics Industry Survey

Therapy:

  • Antibiotic Therapy
  • Fluid Replacement Therapy
  • Bone Marrow Transplantation

End-User:

  • Hospital
  • Homecare
  • Specialty Clinics
  • Others

Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Frequently Asked Questions

What is the Size of The Fucosidosis Therapeutics Market?

In 2023, the market is expected to be worth US$ 10 million.

How the Fucosidosis Therapeutics Market Developed in the Past?

From 2018 to 2022, the global market thrived at a 4% CAGR.

What is the Market Growth Forecast from 2023 to 2033?

The market is expected to continue growth at a 6% CAGR until 2033.

What is the Growth Outlook of the Asia Pacific Market?

The Asia Pacific region is scheduled to expand at a swift pace, with a CAGR of 5%.

How Big Will the Market Be by 2033?

The market is expected to be around US$ 17.91 million by 2033.

Table of Content

1. Executive Summary | Fucosidosis Therapeutics Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Fucosidosis Therapeutics Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Fucosidosis Therapeutics Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Therapy, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Therapy, 2023 to 2033

        5.3.1. Antibiotic Therapy

        5.3.2. Fluid Replacement Therapy

        5.3.3. Bone Marrow Transplantation

    5.4. Y-o-Y Growth Trend Analysis By Therapy, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Therapy, 2023 to 2033

6. Global Fucosidosis Therapeutics Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033

        6.3.1. Hospitals

        6.3.2. Specialty Clinics

        6.3.3. Others

    6.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033

7. Global Fucosidosis Therapeutics Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Europe

        7.3.4. Asia Pacific

        7.3.5. Middle East & Africa (MEA)

    7.4. Market Attractiveness Analysis By Region

8. North America Fucosidosis Therapeutics Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        8.2.1. By Country

            8.2.1.1. USA

            8.2.1.2. Canada

        8.2.2. By Therapy

        8.2.3. By End User

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Therapy

        8.3.3. By End User

    8.4. Key Takeaways

9. Latin America Fucosidosis Therapeutics Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Therapy

        9.2.3. By End User

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Therapy

        9.3.3. By End User

    9.4. Key Takeaways

10. Europe Fucosidosis Therapeutics Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. UK

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Europe

        10.2.2. By Therapy

        10.2.3. By End User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Therapy

        10.3.3. By End User

    10.4. Key Takeaways

11. Asia Pacific Fucosidosis Therapeutics Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. China

            11.2.1.2. Japan

            11.2.1.3. South Korea

            11.2.1.4. Singapore

            11.2.1.5. Thailand

            11.2.1.6. Indonesia

            11.2.1.7. Australia

            11.2.1.8. New Zealand

            11.2.1.9. Rest of Asia Pacific

        11.2.2. By Therapy

        11.2.3. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Therapy

        11.3.3. By End User

    11.4. Key Takeaways

12. MEA Fucosidosis Therapeutics Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. GCC Countries

            12.2.1.2. South Africa

            12.2.1.3. Israel

            12.2.1.4. Rest of MEA

        12.2.2. By Therapy

        12.2.3. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Therapy

        12.3.3. By End User

    12.4. Key Takeaways

13. Key Countries Fucosidosis Therapeutics Market Analysis

    13.1. USA

        13.1.1. Pricing Analysis

        13.1.2. Market Share Analysis, 2022

            13.1.2.1. By Therapy

            13.1.2.2. By End User

    13.2. Canada

        13.2.1. Pricing Analysis

        13.2.2. Market Share Analysis, 2022

            13.2.2.1. By Therapy

            13.2.2.2. By End User

    13.3. Brazil

        13.3.1. Pricing Analysis

        13.3.2. Market Share Analysis, 2022

            13.3.2.1. By Therapy

            13.3.2.2. By End User

    13.4. Mexico

        13.4.1. Pricing Analysis

        13.4.2. Market Share Analysis, 2022

            13.4.2.1. By Therapy

            13.4.2.2. By End User

    13.5. Germany

        13.5.1. Pricing Analysis

        13.5.2. Market Share Analysis, 2022

            13.5.2.1. By Therapy

            13.5.2.2. By End User

    13.6. UK

        13.6.1. Pricing Analysis

        13.6.2. Market Share Analysis, 2022

            13.6.2.1. By Therapy

            13.6.2.2. By End User

    13.7. France

        13.7.1. Pricing Analysis

        13.7.2. Market Share Analysis, 2022

            13.7.2.1. By Therapy

            13.7.2.2. By End User

    13.8. Spain

        13.8.1. Pricing Analysis

        13.8.2. Market Share Analysis, 2022

            13.8.2.1. By Therapy

            13.8.2.2. By End User

    13.9. Italy

        13.9.1. Pricing Analysis

        13.9.2. Market Share Analysis, 2022

            13.9.2.1. By Therapy

            13.9.2.2. By End User

    13.10. China

        13.10.1. Pricing Analysis

        13.10.2. Market Share Analysis, 2022

            13.10.2.1. By Therapy

            13.10.2.2. By End User

    13.11. Japan

        13.11.1. Pricing Analysis

        13.11.2. Market Share Analysis, 2022

            13.11.2.1. By Therapy

            13.11.2.2. By End User

    13.12. South Korea

        13.12.1. Pricing Analysis

        13.12.2. Market Share Analysis, 2022

            13.12.2.1. By Therapy

            13.12.2.2. By End User

    13.13. Singapore

        13.13.1. Pricing Analysis

        13.13.2. Market Share Analysis, 2022

            13.13.2.1. By Therapy

            13.13.2.2. By End User

    13.14. Thailand

        13.14.1. Pricing Analysis

        13.14.2. Market Share Analysis, 2022

            13.14.2.1. By Therapy

            13.14.2.2. By End User

    13.15. Indonesia

        13.15.1. Pricing Analysis

        13.15.2. Market Share Analysis, 2022

            13.15.2.1. By Therapy

            13.15.2.2. By End User

    13.16. Australia

        13.16.1. Pricing Analysis

        13.16.2. Market Share Analysis, 2022

            13.16.2.1. By Therapy

            13.16.2.2. By End User

    13.17. New Zealand

        13.17.1. Pricing Analysis

        13.17.2. Market Share Analysis, 2022

            13.17.2.1. By Therapy

            13.17.2.2. By End User

    13.18. GCC Countries

        13.18.1. Pricing Analysis

        13.18.2. Market Share Analysis, 2022

            13.18.2.1. By Therapy

            13.18.2.2. By End User

    13.19. South Africa

        13.19.1. Pricing Analysis

        13.19.2. Market Share Analysis, 2022

            13.19.2.1. By Therapy

            13.19.2.2. By End User

    13.20. Israel

        13.20.1. Pricing Analysis

        13.20.2. Market Share Analysis, 2022

            13.20.2.1. By Therapy

            13.20.2.2. By End User

14. Market Structure Analysis

    14.1. Competition Dashboard

    14.2. Competition Benchmarking

    14.3. Market Share Analysis of Top Players

        14.3.1. By Regional

        14.3.2. By Therapy

        14.3.3. By End User

15. Competition Analysis

    15.1. Competition Deep Dive

        15.1.1. Baxter

            15.1.1.1. Overview

            15.1.1.2. Product Portfolio

            15.1.1.3. Profitability by Market Segments

            15.1.1.4. Sales Footprint

            15.1.1.5. Strategy Overview

                15.1.1.5.1. Marketing Strategy

        15.1.2. B. Braun Melsungen AG

            15.1.2.1. Overview

            15.1.2.2. Product Portfolio

            15.1.2.3. Profitability by Market Segments

            15.1.2.4. Sales Footprint

            15.1.2.5. Strategy Overview

                15.1.2.5.1. Marketing Strategy

        15.1.3. Fresenius Kabi AG

            15.1.3.1. Overview

            15.1.3.2. Product Portfolio

            15.1.3.3. Profitability by Market Segments

            15.1.3.4. Sales Footprint

            15.1.3.5. Strategy Overview

                15.1.3.5.1. Marketing Strategy

        15.1.4. DJ labs

            15.1.4.1. Overview

            15.1.4.2. Product Portfolio

            15.1.4.3. Profitability by Market Segments

            15.1.4.4. Sales Footprint

            15.1.4.5. Strategy Overview

                15.1.4.5.1. Marketing Strategy

        15.1.5. Lonza Group Ltd

            15.1.5.1. Overview

            15.1.5.2. Product Portfolio

            15.1.5.3. Profitability by Market Segments

            15.1.5.4. Sales Footprint

            15.1.5.5. Strategy Overview

                15.1.5.5.1. Marketing Strategy

        15.1.6. Sanofi-Aventis LLC

            15.1.6.1. Overview

            15.1.6.2. Product Portfolio

            15.1.6.3. Profitability by Market Segments

            15.1.6.4. Sales Footprint

            15.1.6.5. Strategy Overview

                15.1.6.5.1. Marketing Strategy

        15.1.7. AllCells LLC

            15.1.7.1. Overview

            15.1.7.2. Product Portfolio

            15.1.7.3. Profitability by Market Segments

            15.1.7.4. Sales Footprint

            15.1.7.5. Strategy Overview

                15.1.7.5.1. Marketing Strategy

        15.1.8. Merck Millipore Corporation

            15.1.8.1. Overview

            15.1.8.2. Product Portfolio

            15.1.8.3. Profitability by Market Segments

            15.1.8.4. Sales Footprint

            15.1.8.5. Strategy Overview

                15.1.8.5.1. Marketing Strategy

        15.1.9. Stemcell Technologies

            15.1.9.1. Overview

            15.1.9.2. Product Portfolio

            15.1.9.3. Profitability by Market Segments

            15.1.9.4. Sales Footprint

            15.1.9.5. Strategy Overview

                15.1.9.5.1. Marketing Strategy

        15.1.10. American Type Culture Collection Inc.

            15.1.10.1. Overview

            15.1.10.2. Product Portfolio

            15.1.10.3. Profitability by Market Segments

            15.1.10.4. Sales Footprint

            15.1.10.5. Strategy Overview

                15.1.10.5.1. Marketing Strategy

16. Assumptions & Acronyms Used

17. Research Methodology

Recommendations

Healthcare

Leukemia Therapeutics Treatment Market

Published : October 2023

Healthcare

Acrocallosal Syndrome Therapeutics Market

Published : January 2023

Healthcare

Bartonellosis Therapeutics Market

Published : January 2023

Healthcare

Lung Cancer Therapeutics Market

Published : June 2022

Explore Healthcare Insights

View Reports

Fucosidosis Therapeutics Market